Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...